Faslodex spermiogenesis inhibitor

Product Overview

Alternative Name: Antiestrogen ICI 182780, Fulvestrant

Development Status: Inactive

Target: Male

Mode: Hormonal

Delivery Type: Injectable

Duration Type: Short-acting

Description: Faslodex induces infertility by diluting epididymal sperm, without blocking the reproductive tract. Targets estrogen receptor-alpha, dominant in only one region of the male reproductive tract in rats, but not dogs or marmosets at non-toxic doses-- the efferent ductules. Does not target the androgen receptor or testosterone, the dominant male hormone pathway.

Updated date: July 30, 2016

Vertical Tabs

Status

Project Phase: Early Development

Project Stage: Pre-clinical

Status Details:
  • Active ingredient already FDA-approved and on market for the treatment of breast cancer in women. Pre-clinical proof-of-concept studies conducted for male contraceptive use.

Download Product Report